Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

BeOne Medicines Ltd. Director's Dealing 2022

Feb 9, 2022

30073_dirs_2022-02-08_3aa0c56f-b2d2-49b2-bdf4-22a3e28b8182.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2022-02-01

Reporting Person: Dugan Margaret (Director)

More from BeOne Medicines Ltd.

Regulatory Filings 2026
May 15
Regulatory Filings 2026
May 6
Interim / Quarterly Report 2026
May 6
Regulatory Filings 2026
May 6
Annual Report 2026
Apr 28
Proxy Solicitation & Information Statement 2026
Apr 28
Regulatory Filings 2026
Apr 14
Annual Report 2026
Feb 26
Regulatory Filings 2026
Feb 26
Director's Dealing 2026
Feb 6
View all filings →